ArticleFrontiers in big data2026
Detection and classification of lung cancer using sequential hybridization of CNN and RNN type architectures.
Article in Frontiers in big data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early and accurate lung cancer detection from computed tomography (CT) images remains a challenging task because of the complex morphology of lung nodules, class imbalance, variation in image quality, and the risk of overfitting in deep learning models. Conventional manual interpretation is time-consuming and may be affected by inter-observer variability. Therefore, an automated and reliable CT-based classification framework is required to support early identification of benign, malignant, and normal lung conditions. Methods: This study proposes a sequential hybrid deep learning framework that integrates convolutional and recurrent neural network components for multiclass lung cancer classification. A dataset of 1,600 CT-scan images collected from multiple hospital data repositories across Bengaluru was used and divided in an approximate 70:30 ratio for training and validation. The preprocessing pipeline includes contrast enhancement using Contrast Limited Adaptive Histogram Equalization (CLAHE), morphological operations for lung segmentation, and nodule-focused masking to isolate diagnostically relevant lung regions. Data augmentation and transfer learning were applied to improve model generalization and reduce overfitting. DenseNet201 was used for feature extraction, while a bidirectional gated recurrent unit (BiGRU) module was incorporated for sequential representation learning. Hyperparameter optimization and early stopping were used to improve training stability and classification performance. Results: The proposed DenseNet201-BiGRU sequential hybrid architecture achieved an overall accuracy of 95.8%. The class-wise accuracies were 97.33% for benign cases, 93.33% for malignant cases, and 96.67% for normal cases. Precision, recall, and F1-score values further demonstrated that the model maintained reliable classification performance across diverse and imbalanced CT image classes. Discussion: The results indicate that sequential hybridization of DenseNet201-based feature extraction with BiGRU-based representation learning provides an efficient, precise, and robust framework for CT-based lung cancer classification. The proposed method improves classification reliability by combining enhanced preprocessing, focused lung-region extraction, transfer learning, and recurrent modeling. However, further validation using larger, multi-center datasets and additional clinical testing is required before real-world deployment and broader diagnostic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.